*Application closing date has been extended for this project*
Androgen Deprivation Therapy (ADT) and radiotherapy combination is highly effective in patients with locally-advanced prostate cancer, yet >30% of patients relapse within 3- years. This project aims to use cutting edge genomic methods and state of the art models to explore the potential of to improve efficacy of these treatments through exploiting effects on cell death and anti-tumour immunity.
The combination of Androgen Deprivation Therapy (ADT) and radiotherapy is highly effective in patients with locally-advanced prostate cancer (LAPC), yet >30% of patients relapse within 3-years. Therefore, strategies to treat or prevent development of ADT/radiotherapy-refractory prostate cancers are becoming increasingly important.
Emerging data have identified epigenetic changes in gene expression as a major differentiator between aggressive and indolent disease, wherein treatment-induced, epigenetic-driven transcriptional changes underpin adaptive tumour cell survival responses and immune escape mechanisms, ultimately leading to patient relapse.
We have strong preliminary data to support our hypothesis that treatments targeting a range of clinically relevant epigenetic modifiers may be particularly effective in improving response to SoC ADT/Radiotherapy (ADT/Rad). The aim of this PhD is to use cutting edge genomic methods and state of the art models to further explore the mechanisms thorugh which these combinations induce cell death and anti-tumour immunity to inform clinical studies to ultimately benefit men with prostate cancer.
Funding eligibility: ROI (and EU applicants with pre-settled/settled) status may be eligible for funding. Please review the DfE T&C’s.
ENTRY REQUIREMENTS
You must hold or expect to get an upper second class honours degree from a university in the UK or Ireland, or qualifications and experience considered by the University as equivalent to that standard. Candidates who already hold a doctoral degree, or who have registered on a PhD for one year (or part-time equivalent) or not eligible.
English Language
Candidates applying from countries where the first language is not English should produce evidence of their competence through a qualification such as IELTS or TOEFL score.
The minimum recommended score for the School of Medicine, Dentistry and Biomedical Science is:
· IELTS score of 6.0 with not less than 5.5 in each of the four component elements of listening, reading, speaking and writing taken within the last 2 years;
· TOEFL score of 80+ (internet basted test), taken within the last 2 years, with minimum component scores of; Listening 17, Reading 18, Speaking 20, Writing 17);
· A valid Certificate of Proficiency in English grade A or B;
· A valid Certificate of Advanced English grade A; or
· A first or upper second class honours degree from a university based in the UK, Republic of Ireland or other suitably quality assured location in a country deemed by the UK Border Agency to be majority English speaking.
For a list of English Language qualifications also accepted by the School and University please see the following link:
http://www.qub.ac.uk/International/International-students/Applying/English-language-requirements/#English
INTO Queen’s English Language Courses offers both pre-sessional and in-sessional courses in English for academic purposes and study skills. Courses vary in length and full information can be obtained at: https://www.qub.ac.uk/International/International-students/Applying/University-Preparation-Courses/INTOEnglishlanguagecoursesatQueens/
Continue with Facebook
